Johnson & Johnson (JNJ)vsMaravai Lifesciences Holdings Inc (MRVI)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
MRVI
Maravai Lifesciences Holdings Inc
$6.53
-2.97%
HEALTHCARE · Cap: $2.73B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 46806% more annual revenue ($97.93B vs $208.78M). JNJ leads profitability with a 21.5% profit margin vs -37.1%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
MRVI
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Intrinsic value data unavailable for MRVI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Weak financial health signals
ROE of -49.4% — below average capital efficiency
Earnings declined 32.7%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : MRVI
MRVI has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MRVI
The primary concerns for MRVI are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MRVI is a turnaround play — different risk/reward profiles.
MRVI carries more volatility with a beta of 0.58 — expect wider price swings.
MRVI is growing revenue faster at 8.5% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 22/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Maravai Lifesciences Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?